Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors

Biochemical Pharmacology

Volumn 75, Issue 2, 2008, Pages 405-413

  Turner, Stephanie J ^a   Zhuang, Shunhui ^a   Zhang, Tong ^a   Boss, Gerry R ^a   Pilz, Renate B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

HMG CoA reductase inhibitor; Leukemia cells; Prenylation; Rho activity; Rho guanine nucleotide dissociation inhibitor; Rho isoforms

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR; MEVINOLIN; RHO FACTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHOLESTEROL SYNTHESIS; DRUG EFFECT; DRUG MECHANISM; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; PRENYLATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

CELL LINE, TUMOR; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; GUANOSINE TRIPHOSPHATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; PROTEIN PRENYLATION; RHO GTP-BINDING PROTEINS; RHOA GTP-BINDING PROTEIN; RHOB GTP-BINDING PROTEIN; TRANSCRIPTION, GENETIC;

EID: 37349013346     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.08.031     Document Type: Article

References (39)

1. Sahai E., and Marshall C.J. Rho-GTPases and cancer. Nat Rev Cancer 2 (2002) 133-142
2. Dovas A., and Couchman J.R. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J 390 (2005) 1-9
3. Chen J.C., Zhuang S., Nguyen T.H., Boss G.R., and Pilz R.B. Oncogenic Ras leads to Rho activation by activating the mitogen-activated protein kinase pathway and decreasing Rho-GTPase-activating protein activity. J Biol Chem 278 (2003) 2807-2818
4. rho proteins. J Biol Chem 267 (1992) 20033-20038
5. Hori Y., Kikuchi A., Isomura M., Katayama M., Miura Y., Fujioka H., Kaibuchi K., and Takai Y. Post-translational modifications of the C-terminal region of the rho protein are important for its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins. Oncogene 6 (1991) 515-522
6. Solski P.A., Helms W., Keely P.J., Su L., and Der C.J. RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. Cell Growth Differ 13 (2002) 363-373
7. Allal C., Favre G., Couderc B., Salicio S., Sixou S., Hamilton A.D., Sebti S.M., Lajoie-Mazenc I., and Pradines A. RhoA prenylation is required for promotin of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription. J Biol Chem 275 (2000) 31001-31008
8. Wang D.A., and Sebti S.M. Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities. J Biol Chem 280 (2005) 19243-19249
9. Wong W.W., Dimitroulakos J., Minden M.D., and Penn L.Z. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16 (2002) 508-519
10. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45 (2005) 89-118
11. Thibault A., Samid D., Tompkins A.C., Figg W.D., Cooper M.R., Hohl R.J., Trepel J., Liang B., Patronas N., Venzon D.J., Reed E., and Myers C.E. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2 (1996) 483-491
12. Eto M., Kozai T., Cosentino F., Joch H., and Luscher T.F. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105 (2002) 1756-1759
13. del Real G., Jimenez-Baranda S., Mira E., Lacalle R.A., Lucas P., Gomez-Mouton C., et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 200 (2004) 541-547
14. Kusama T., Mukai M., Ayaki M., Imamura F., Tatsuta M., Matsumoto Y., et al. Inhibition of lysophosphatidic acid-induced RhoA activation and tumor cell invasion by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Int J Oncol 23 (2003) 1173-1178
15. Cordle A., Koenigsknecht-Talboo J., Wilkinson B., Limpert A., and Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280 (2005) 34202-34209
16. Porter K.E., Turner N.A., O'Regan D.J., Balmforth A.J., and Ball S.G. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc Res 61 (2004) 745-755
17. Ren X.-D., Kiosses W.B., and Schwartz M.A. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J 18 (1999) 578-585
18. Gudi T., Chen J.C., Casteel D.E., Seasholtz T.M., Boss G.R., and Pilz R.B. cGMP-dependent protein kinase inhibits serum response element-dependent transcription by inhibiting Rho activation and functions. J Biol Chem 277 (2002) 37382-37393
19. Jakobisiak M., Bruno S., Skierski J.S., and Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88 (1991) 3628-3632
20. Bordier C. Phase separation of integral membrane proteins in triton X-114 solution. J Biol Chem 256 (1981) 1604-1607
21. Zeng Y., Zhuang S., Gloddek J., Tseng C.C., Boss G.R., and Pilz R.B. Regulation of cGMP-dependent protein kinase expression by Rho and Kruppel-like transcription factor-4. J Biol Chem 281 (2006) 16951-16961
22. Zhang B., Zhang Y., Dagher M.C., and Shacter E. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis. Cancer Res 65 (2005) 6054-6062
23. Molnar G., Dagher M.C., Geiszt M., Settleman J., and Ligeti E. Role of prenylation in the interaction of Rho-family small GTPases with GTPase activating proteins. Biochemistry 40 (2001) 10542-10549
24. Hancock J.F., and Hall A. A novel role for RhoGDI as an inhibitor of GAP proteins. EMBO J 12 (1993) 1915-1921
25. Michaelson D., Silletti J., Murphy G., D'Eustachio P., Rush M., and Philips M.R. Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding. J Cell Biol 152 (2001) 111-126
26. Gorvel J.P., Chang T.C., Boretto J., Azuma T., and Chavrier P. Differential properties of D4/LyGDI versus RhoGDI: phosphorylation and rho GTPase selectivity. FEBS Lett 422 (1998) 269-273
27. Zalcman G., Closson V., Camonis J., Honore N., Rousseau-Merck M.F., Tavitian A., et al. RhoGDI-3 is a new GDP dissociation inhibitor (GDI). Identification of a non-cytosolic GDI protein interacting with the small GTP-binding proteins RhoB and RhoG. J Biol Chem 271 (1996) 30366-30374
28. Holstein S.A., Wohlford-Lenane C.L., and Hohl R.J. Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB. J Biol Chem 277 (2002) 10678-10682
29. Cen B., Selvaraj A., Burgess R.C., Hitzler J.K., Ma Z.G., Morris S.W., et al. Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes. Mol Cell Biol 23 (2003) 6597-6608
30. Winter-Vann A.M., and Casey P.J. Opinion - post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 5 (2005) 405-412
31. Lewis K.A., Holstein S.A., and Hohl R.J. Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leuk Res 29 (2005) 527-533
32. Zhong W.B., Wang C.Y., Chang T.C., and Lee W.S. Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 144 (2003) 3852-3859
33. Lebowitz P.F., Casey P.J., Prendergast G.C., and Thissen J.A. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 272 (1997) 15591-15594
34. Orita S., Kaibuchi K., Kuroda S., Shimizu K., Nakanishi H., and Takai Y. Comparison of kinetic properties between two mammalian ras p21 GDP/GTP exchange proteins, ras guanine nucleotide-releasing factor and smg GDP dissociation stimulator. J Biol Chem 268 (1993) 25542-25546
35. Ohkawara H., Ishibashi T., Sakamoto T., Sugimoto K., Nagata K., Yokoyama K., et al. Thrombin-induced rapid geranylgeranylation of RhoA as an essential process for RhoA activation in endothelial cells. J Biol Chem 280 (2005) 10182-10188
36. Yokoyama K., Ishibashi T., Ohkawara H., Kimura J., Matsuoka I., Sakamoto T., et al. HMG-CoA reductase inhibitors suppress intracellular calcium mobilization and membrane current induced by lysophosphatidylcholine in endothelial cells. Circulation 105 (2002) 962-967
37. Vecchione C., and Brandes R.P. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 91 (2002) 173-179
38. Kuroda Y., Suzuki N., and Kataoka T. The effect of posttranslational modifications on the interaction of Ras2 with adenylyl cyclase 1. Science 259 (1993) 683-686
39. Lerner E., Qian Y., Blaskovich M., Fossum R., Vogt A., Sun J., et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 270 45 (1995) 26802-26806